NCT04891198 2026-03-25
ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors
3D Medicines
Phase 2 Recruiting
Clinical Trials
6 trialsNCT07260305 2025-12-03
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients
Kangabio AUSTRALIA LTD PTY
Phase 1 Recruiting
NCT06074497 2025-02-07
This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy with Envafolimab in Patients with Advanced or Metastatic Solid Tumors.
Kangabio AUSTRALIA LTD PTY
Phase 1 Active not recruiting
NCT03101488 2022-03-03
Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors
3D Medicines
Phase 1 Completed
NCT03248843 2022-02-08
A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
3D Medicines
Phase 1 Completed
NCT02827968 2021-06-02
Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors
3D Medicines
Phase 1 Completed